Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Return on Sales (2016 - 2025)

Historic Return on Sales for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to 9.53%.

  • Pharma's Return on Sales fell 53700.0% to 9.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.83%, marking a year-over-year increase of 48000.0%. This contributed to the annual value of 5.6% for FY2025, which is 40600.0% up from last year.
  • As of Q3 2025, Pharma's Return on Sales stood at 9.53%, which was down 53700.0% from 4.88% recorded in Q2 2025.
  • Over the past 5 years, Pharma's Return on Sales peaked at 3.63% during Q1 2025, and registered a low of 77.57% during Q3 2021.
  • Its 5-year average for Return on Sales is 18.47%, with a median of 9.78% in 2024.
  • Examining YoY changes over the last 5 years, Pharma's Return on Sales showed a top increase of 723500bps in 2021 and a maximum decrease of -643200bps in 2021.
  • Pharma's Return on Sales (Quarter) stood at 16.77% in 2021, then skyrocketed by 60bps to 6.77% in 2022, then plummeted by -304bps to 27.4% in 2023, then surged by 74bps to 7.12% in 2024, then crashed by -34bps to 9.53% in 2025.
  • Its Return on Sales stands at 9.53% for Q3 2025, versus 4.88% for Q2 2025 and 3.63% for Q1 2025.